ClinicalTrials.gg
Active, not recruitingNCT02000284MitoUpdated Jan 22, 2026

Mitochondrial Dysfunction in Autism Spectrum Disorder

An observational study in Autism Spectrum Disorder, Autism and Mitochondrial Disease, sponsored by University of Arkansas. Active, not recruiting at 1 site in United States. Open to participants aged 0 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.

Primary conditionAutistic DisorderRegistry: Autism Spectrum DisorderReclassifiedWhy we changed it
Registry
Autism Spectrum Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autistic Disorder
Why
  1. The study's listed conditions name Autistic Disorder, a narrower term within Autism Spectrum Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Arkansas · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
297
Ages
0 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 604 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Enrollment
34th of 96
297 · median 135
Started
2012
with 25 others
Observational
96 of 604
15 open now
Primary completion
2026-12
later than 47 of 150 live
Registered
242nd of 604
by date

Among the 604 studies in Autistic Disorder with a site in United States, this one is the 34th largest by enrollment of the 96 observational ones that give a count, is one of 26 that started in 2012, is one of 96 observational ones, reaches primary completion later than 47 of the 150 other live ones, and was the 242nd registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 604 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 0 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 604 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

Researchers at Arkansas Children's Hospital Research Institute are conducting a study about mitochondrial function in children. The study involves up to 5 visits to Arkansas Children's Hospital with fasting blood draws, behavioral assessments, and/or questionnaires.

This study is not currently recruiting, but continues to follow those who were enrolled.

There is no cost for visits or study-related exams.

For further information, please contact the program manager, Leanna Delhey, at ldelhey@uams.edu or 501-364-4519

Read the detailed description

Objective: The main objective of this proposal is to develop a minimally-invasive biological assay that can be widely used to identify variations in mitochondrial function and dysfunction in children with autism spectrum disorder (ASD). This assay will allow the investigators to determine the true range of mitochondrial function and dysfunction across a population of children with ASD. The relationship between mitochondrial function and dysfunction in ASD, redox metabolism and core ASD symptomology will also be investigated. To understand the true variation in mitochondrial function and its relationship to cognitive development and autism symptoms, participants will be evaluated at two time points to understand the within subject variation of mitochondrial measurements.

Specific Aims: 1) To develop a minimally-invasive assay that can accurately identify children with ASD/MD from the general ASD population. 2) To establish whether there is simply an ASD/MD subgroup or whether mitochondrial dysfunction occurs on a spectrum from mild to severe in ASD. 3) To determine the relationship between mitochondrial function and redox metabolism in children with ASD. 4) To evaluate the effect of mitochondrial dysfunction and glutathione redox status on language and social development and ASD symptoms.

Study Design: Using the Seahorse Analyzer, investigators will develop profiles of mitochondrial function for individuals with ASD and known MD (ASD/MD) and individuals with ASD known not to have MD (ASD/NoMD). These two groups will serve as the two ends of the spectrum of mitochondrial function in children with ASD and will be compared to profiles from TD children. Investigators will then examine the profiles of mitochondrial function in a general population of individuals with ASD to determine how these individuals fall into this spectrum defined by the ASD/MD and ASD/NoMD groups, as well as DD and no ASD/MD. Glutathione redox metabolism will be measured in all participants. The relationship between mitochondrial function, redox metabolism and core ASD symptoms will be studied in the ASD groups with particular attention to whether ASD symptoms, language ability and adaptive behavior are directly related to mitochondrial function or indirectly related to mitochondrial function through its effect on redox metabolism.

Study Population: Investigators will recruit several groups of children for this study: 50 children with ASD who have MD (ASD/MD); 50 children with ASD who do not have MD (ASD/NoMD); 50 no ASD/MD; 50 no ASD/no MD but DD; 100 TD controls; and a general population of 150 children with ASD.

Children with ASD with and without MD will be identified in the autism multispecialty clinic (AMC), as well as the ATN and other medical clinics that evaluate children with ASD in outpatient clinics in Arkansas. When a child is identified, the study coordinator will contact the parents and describe the study. If the parents are interested, the coordinator will screen by asking inclusion/exclusion criteria questions. If the child qualifies, the coordinator will schedule the visit and mail consent forms to the parents for their review. During the visit they will undergo a blood draw for metabolic testing. The child will then be sent to breakfast since the blood tests require collection prior to breakfast. After breakfast the participant will undergo further language and behavioral assessment while the parent will be interviewed for the Vineland and other questionnaires. The parents will be provided questionnaires for the teacher to fill out and mail in an addressed, postage paid envelope.

For the TD participants, these children will be recruited in several ways including using social media through Arkansas Children's Hospital, flyers posted in the community (i.e. primary pediatric clinics), as well as referrals from pediatricians. When a child is identified, the study coordinator will contact the parents and describe the study. If the parents are interested, the coordinator will screen by asking inclusion/exclusion criteria questions. If the child qualifies, the coordinator will schedule the visit and mail consent forms to the parents for their review. During the visit they will undergo a blood draw for metabolic testing.

03

Conditions studied

  • Autism Spectrum Disorder
  • Autism
  • Mitochondrial Disease
  • Developmental Delay

Keywords

  • Autism Spectrum Disorder
  • ASD
  • Autism
  • Pervasive developmental disorder - Not Otherwise Specified
  • PDD-NOS
  • Asperger's Syndrome
  • Mitochondrial Disease
  • Developmental Delay
  • Typical Development
04

In context

Autistic Disorder Reclassified

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

This study's enrollment of 297 is above the median of 102 across 191 observational studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

University of Arkansas is the lead sponsor of 399 studies on the registry; 38 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 35 (95%) have results posted.

Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We will recruit several groups of children for this study: 50 children with ASD who have MD (ASD/MD); 50 children with ASD who do not have MD (ASD/NoMD); 50 no ASD/MD; 50 no ASD/no MD but DD; 100 TD controls; and a general population of 150 children with ASD.

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria for ASD children

  1. Autism Spectrum Disorder (As defined by a gold standard measure for ASD diagnosis: the Autism Diagnostic Observation Schedule, Autism Diagnostic Interview, and/or the minimum Arkansas state requirement for autism classification, as defined by a consensus diagnosis of ASD by a medical doctor, speech pathologist, and psychologist.). In an event where sufficient diagnostic information is lacking, and the PI believes that the clients meet all other inclusion criteria and a prospective diagnosis of an ASD is clinically warranted, and a formal diagnosis is scheduled to occur within a reasonable time frame from the date of study entry, then the client may be considered as potentially eligible.
  2. 0 years through 17 years 11 months of age

Inclusion Criteria for TD children

1. 0 years to 17 years 11 months of age

Exclusion Criteria:

  • Discussed on a case by case basis
06

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
297 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • General ASD

    150 general ASD children

  • ASD/MD

    50 children Diagnosed with an Autism Spectrum Disorder and a Mitochondrial Disorder

  • ASD/noMD

    50 children with ASD that have been r/o as having a mitochondrial disorder

  • MD/noASD

    50 children with a mitochondrial disorder and without an ASD

  • Developmental Delay

    50 children without a mitochondrial disorder or autism spectrum disorder, but with general developmental delays

  • Typically Developing

    100 children with no history of medical, behavioral, or immunological disorders

07

What researchers measure

Primary outcomes

  1. Mitochondrial Reserve Capacity measured using the Seahorse XR Flux Analyzer

    Children with ASD will be differentiated from all other cohorts and have a specific pattern of mitochondrial dysfunction that will be different from and comparable to other groups of children in the study (e.g. mitochondrial disease without autism, typically developing, autism with mitochondrial disease, and developmental delay). It is hypothesized that these children will have a more pronounced delay in their development and will have a higher probability for poor developmental and behavioral outcomes. This will be evaluated using a Seahorse VR flux analyzer to generate a maximal reserve capacity value.

    Time frame: up to one year

08

Study locations

1 site
09

References and documents

Publications

  • Frye RE, Lionnard L, Singh I, Karim MA, Chajra H, Frechet M, Kissa K, Racine V, Ammanamanchi A, McCarty PJ, Delhey L, Tippett M, Rose S, Aouacheria A. Mitochondrial morphology is associated with respiratory chain uncoupling in autism spectrum disorder. Transl Psychiatry. 2021 Oct 13;11(1):527. doi: 10.1038/s41398-021-01647-6. PubMed 34645790 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2012 (actual). Primary completion is estimated for Dec 2026, 170 months after the start.

Of 57 non-industry observational studies under Autistic Disorder, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 170 months is above that.

Counting every sponsor, half of 65 studies reached it within 43 months; a quarter within 20 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2013
First posted
Dec 4, 2013
StartActual
Oct 16, 2012
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02000284
Collaborators
Jane Botsford Johnson Foundation, Arkansas Biosciences Institute, The University of Texas Health Science Center at San Antonio, St. Christopher's Hospital for Children, The BRAIN Foundation
Responsible party
Sponsor
First posted
Dec 4, 2013
Start date
Oct 16, 2012
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 22, 2026

Study contacts

Shannon Rose, PhD
principal investigator · The University of Tennessee Health Science Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion